Affiliation:
1. Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract
MicroRNAs (miRNA) are small non-coding RNAs that act as one of the main regulators of
gene expression. They are involved in maintaining a proper balance of diverse processes, including differentiation,
proliferation, and cell death in normal cells. Cancer biology can also be affected by these
molecules by modulating the expression of oncogenes or tumor suppressor genes. Thus, miRNA based
anticancer therapy is currently being developed either alone or in combination with chemotherapy
agents used in cancer management, aiming at promoting tumor regression and increasing cure rate.
Access to large quantities of RNA agents can facilitate RNA research and development. In addition to
currently used in vitro methods, fermentation-based approaches have recently been developed, which
can cost‐effectively produce biological RNA agents with proper folding needed for the development of
RNA-based therapeutics. Nevertheless, a major challenge in translating preclinical studies to clinical
for miRNA-based cancer therapy is the efficient delivery of these agents to target cells. Targeting
miRNAs/anti-miRNAs using antibodies and/or peptides can minimize cellular and systemic toxicity.
Here, we provide a brief review of miRNA in the following aspects: biogenesis and mechanism of action
of miRNAs, the role of miRNAs in cancer as tumor suppressors or oncogenes, the potential of using
miRNAs as novel and promising therapeutics, miRNA-mediated chemo-sensitization, and currently
utilized methods for the in vitro and in vivo production of RNA agents. Finally, an update on the viral
and non-viral delivery systems is addressed.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmaceutical Science,Biotechnology
Reference152 articles.
1. Takahashi R.U.; Prieto-Vila M.; Kohama I.; Ochiya T.; Development of miRNA-based therapeutic approaches for cancer patients. Cancer Sci 2019,110(4),1140-1147
2. Zhao S.; Chen H.; Ding B.; Li J.; Lv F.; Han K.; Zhou D.; Yu B.; Yu Y.; Zhang W.; Construction of a transcription factor-long non-coding RNA-microRNA network for the identification of key regulators in lung adenocarcinoma and lung squamous cell carcinoma. Mol Med Rep 2019,19(2),1101-1109
3. Shah M.Y.; Ferrajoli A.; Sood A.K.; Lopez-Berestein G.; Calin G.A.; microRNA therapeutics in cancer-an emerging concept. EBioMedicine 2016,12,34-42
4. Trang P.; Medina P.P.; Wiggins J.F.; Ruffino L.; Kelnar K.; Omotola M.; Homer R.; Brown D.; Bader A.G.; Weidhaas J.B.; Slack F.J.; Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010,29(11),1580-1587
5. Ho P.Y.; Yu A.M.; Bioengineering of noncoding RNAs for research agents and therapeutics. Wiley Interdiscip Rev RNA 2016,7(2),186-197
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献